Research graph
References from A novel humanized FIX/FX hemophilia A mouse model for preclinical evaluation of FVIIIa-mimetic bispecific antibodies. Local targets link to admitted publications; unresolved targets remain external evidence.
Hemophilic arthropathy
10.5435/00124635-200407000-00004 · 2004 · External reference
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing
10.1016/s0140-6736(20)32722-7 · 2021 · External reference
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
10.1182/blood.2019001869 · 2019 · External reference
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors
10.1182/bloodadvances.2017006684 · 2017 · External reference
Emicizumab prophylaxis in patients who have hemophilia A without inhibitors
10.1056/nejmoa1803550 · 2018 · External reference
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
10.1016/s2352-3026(19)30054-7 · 2019 · External reference
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
10.1182/blood.2020009217 · 2021 · External reference
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
10.1111/hae.14363 · 2021 · External reference
Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5)
10.1002/rth2.12670 · 2022 · External reference
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study
10.1016/s2352-3026(22)00377-5 · 2023 · External reference
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial
10.1182/blood.2023021832 · 2024 · External reference
Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY)
10.1002/rth2.12837 · 2022 · External reference
A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
10.1111/hae.13848 · 2019 · External reference
Real-world bleeding rates on emicizumab: the value of using nationwide digital treatment diary data in clinical research
10.1016/j.rpth.2025.102717 · 2025 · External reference
Emicizumab state-of-the-art update
10.1111/hae.14524 · 2022 · External reference
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
10.1038/nm.2942 · 2012 · External reference
Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation
10.1111/jth.12474 · 2014 · External reference
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
10.1038/ng0595-119 · 1995 · External reference
Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene
10.1111/jth.13202 · 2016 · External reference
Current animal models of hemophilia: the state of the art
10.1186/s12959-016-0106-0 · 2016 · External reference
A hemophilia A mouse model for the in vivo assessment of emicizumab function
10.1182/blood.2019004334 · 2020 · External reference
APTT reagent with ellagic acid as activator shows adequate lupus anticoagulant sensitivity in comparison to silica-based reagent
10.1111/j.1538-7836.2012.04906.x · 2012 · External reference
Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside
10.1021/bi00507a028 · 1981 · External reference
Development of a calibrated automated thrombography based thrombin generation test in mouse plasma
10.1111/j.1538-7836.2007.02719.x · 2007 · External reference
CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice
10.1038/s41598-017-04625-5 · 2017 · External reference
A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A
10.1371/journal.pone.0083280 · 2013 · External reference
Extravascular coagulation regulates haemostasis independently of activated platelet surfaces in an in vivo mouse model
10.1038/s42003-025-07838-x · 2025 · External reference
A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII
10.1182/blood-2014-02-555151 · 2014 · External reference
Hemophilia B (factor IX deficiency)
10.1016/j.hoc.2021.07.008 · 2021 · External reference
Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics
10.1007/s11239-021-02456-w · 2021 · External reference
A novel humanized hemophilia-a mouse model to facilitate preclinical in vivo studies of human specific Fviiia-mimetic bispecific antibodies
10.1182/blood-2018-99-119012 · 2018 · External reference
The influence of SV40 polyA on gene expression of baculovirus expression vector systems
10.1371/journal.pone.0145019 · 2015 · External reference
Additional factor X enhances emicizumab-driven coagulation function in patients with hemophilia A and hemophilia A mice
10.1055/a-2315-8199 · 2025 · External reference
